Luteinizing hormone is independently associated with high‐sensitive cardiac troponin T elevation in postmenopausal T2DM patients: A cross‐sectional study

Abstract

Abstract Background It is known that the risk of ischemic heart disease increases in patients with type 2 diabetes mellitus (T2DM). For female patients, the incidence of heart disease can be even greater after menopause, accompanied by dramatic changes in sex hormones. We investigated the correlations between sex hormones and markers of ischemic heart diseases in postmenopausal females with T2DM patients. Methods This cross‐sectional study collected data from 324 hospitalized postmenopausal females with T2DM. Multiple linear regression analyses were conducted to determine the correlations between sex hormones and cardiac markers including high‐sensitive cardiac troponin T (hs‐cTnT) and N‐terminal prohormone of brain natriuretic peptide (NT‐proBNP) levels. Results Multiple linear regression analyses revealed that luteinizing hormone (LH) was positively and independently associated with hs‐cTnT concentrations in postmenopausal females with T2DM (β = 0.189, p = 0.002). Postmenopausal females with T2DM and subclinical myocardial injury had higher LH levels than those without subclinical myocardial injury (29.67 vs. 25.08 mIU/mL, p 0.05). Neither estrogen nor testosterone was correlated with cardiac markers. Conclusions Elevated LH levels were positively and independently associated with increased hs‐cTnT levels in postmenopausal women with T2DM. Our findings suggest that LH could serve as a potential marker for assessing the risk of subclinical myocardial injury in postmenopausal females with T2DM.

Keywords

• hs‐cTnT
• luteinizing hormone
• postmenopause
• subclinical myocardial necrosis
• type 2 diabetes mellitus